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QIAD assay for quantitating a 
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Susanne A. Funke1,8, Luitgard Nagel-Steger1,2 & Dieter Willbold1,2
Strong evidence exists for a central role of amyloid β-protein (Aβ) oligomers in the pathogenesis 
of Alzheimer’s disease. We have developed a fast, reliable and robust in vitro assay, termed QIAD, 
to quantify the effect of any compound on the Aβ aggregate size distribution. Applying QIAD, we 
studied the effect of homotaurine, scyllo-inositol, EGCG, the benzofuran derivative KMS88009, 
ZAβ3W, the D-enantiomeric peptide D3 and its tandem version D3D3 on Aβ aggregation. The 
predictive power of the assay for in vivo efficacy is demonstrated by comparing the oligomer 
elimination efficiency of D3 and D3D3 with their treatment effects in animal models of Alzheimer´s 
disease.
Alzheimer’s disease (AD) is a progressive neurodegenerative disorder, which is the most common cause 
of dementia. Growing evidence exists that instead of amyloid β -protein (Aβ ) monomers or fibrils, small 
and diffusible Aβ oligomers seem to be decisive for disease development and progression1. Thus, the 
potency to eliminate Aβ oligomers is one of the most desirable criteria for the selection of agents as 
lead compounds for drug development towards AD treatment2. Any screening for oligomer eliminating 
compounds requires a well characterized target. Therefore, new methods for the preparation, purification 
and quantification of specific Aβ oligomers, which are representative for the toxic oligomers involved in 
AD pathogenesis, are urgently needed in AD drug development. Quantitative assessment of Aβ assembly 
size-distributions is difficult, because the heterogeneity of in vitro obtained Aβ assemblies3 impedes most 
of the standard analytical methods.
We have designed an assay for the quantitative determination of interference with Aβ aggregate size 
distribution (QIAD). The QIAD assay, based on a combination of density gradient ultracentrifugation 
(DGC) and reversed phase high performance liquid chromatography (RP-HPLC), permits the quanti-
tative analysis of the impact of any compound on Aβ aggregation. We applied QIAD on several com-
pounds, i.e., homotaurine, scyllo-inositol, EGCG, the benzofuran derivative KMS88009, ZAβ 3W, the 
D-enantiomeric peptide D3, and its tandem version D3D3. Comparison of QIAD data obtained for D3 
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and D3D3 with the treatment effects in AD animal models demonstrates the predictive power of the 
assay for in vivo efficacy.
Results and Discussion
The principle of the QIAD assay. The QIAD assay consists of the following steps (Fig. 1): i) prepa-
ration of Aβ (1-42) assemblies containing the target aggregate species by Aβ (1-42) pre-incubation; ii) 
incubation with and without the agent of interest; iii) separation of Aβ (1–42) assemblies by DGC and 
subsequent fractionation; and iv) determination of the total Aβ (1–42) amount in each fraction, e.g. 
by integrating the Aβ (1–42) absorption signal during RP-HPLC analysis. The essential requirement for 
the quantitative analysis of different Aβ (1–42) aggregates is total disassembly of all different Aβ (1–42) 
assemblies. We were able to achieve this by the harsh conditions during the RP-HPLC runs (presence 
of acetonitrile and column heating to 80 °C) converting all Aβ assemblies into a single species with 
the same retention time. Thus, the integrated peak area of this peak correlates with total Aβ (1–42) 
amount (Fig.  2a). The obtained results indicate that under these conditions the integrated peak areas 
were independent from Aβ (1–42) incubation time and thus independent from its aggregation state. 
Prior to RP-HPLC DGC allows matrix-free separation and fractionation of different Aβ (1–42) assem-
blies according to their sedimentation coefficients, which are dependent on particle size and shape4,5. 
Alternatively the Aβ (1–42) aggregate size distribution could have been studied by a combination of SEC 
(Size Exclusion Chromatography) and MALS (Multi-Angle Light Scattering) detection. Such approach 
seems to be more convenient since it would take less time for a single sample and the direct outcome 
would be a distribution of molecular masses instead of sedimentation coefficients. Nevertheless, DGC 
was superior to SEC/MALS with regard to the recovery rates of Aβ (1–42). Possible interactions of 
Aβ (1–42) with the column matrix and the necessity of either an online filtration or centrifugation step 
prior to chromatography might be responsible for material losses. Aβ (1–42) fibrils, huge aggregates or 
huge complexes (Aβ /ligand) could not pass through in the AD research field prevalent SEC columns with 
a void volume of 75 or 200 kDa. For DGC the whole sample can be loaded onto the gradient regardless 
of the aggregation state of the sample. Additionally, the fact, that for each sample a fresh gradient is pre-
pared, while SEC columns have to be reused, contributes clearly to the very good reproducibility of the 
analysis. We used steps (i) to (iii) previously to investigate the effect of agent candidates on size distri-
bution of Aβ (1–42) aggregates formed in vitro, although only in a qualitative or semi-quantitative way6. 
Here, for the first time, we add the fully quantitative analysis of a compound’s impact on the Aβ (1–42) 
aggregate size distribution and call it QIAD assay (Fig. 2b,c). The principle of the QIAD assay can easily 
be transferred to measure the quantitative interference on aggregates consisting of aggregation-prone 
peptides or proteins other than Aβ . Thus, to avoid any confusion with QIAD variants yet to come, we 
have termed the Aβ -specific QIAD assay “Aβ -QIAD”.
The method abstains from monomeric initial conditions, instead it starts from a reproducibly adjust-
able assembly state, where Aβ (1–42) oligomers are enriched by a pre-incubation step. While Aβ recovery 
rates are rarely demonstrated7 in the AD research field, the herein described procedure reliably yielded 
total Aβ (1–42) recovery rates close to 100%, i.e., 95.6 ± 7.9% for control DGC runs (Aβ without agent) 
and 89.2 ± 16.1% for DGC runs in the presence of D3 or D3D3. Moreover, the method described here 
allows the quantification of yields for any DGC-separated Aβ (1–42) fraction within the sample. For 
example, the average amount of the Aβ (1–42) oligomers (fractions 4 to 6) in eleven independent prepa-
rations was 31.7 ± 3.9%.
Characterisation of Aβ oligomers. Aβ (1–42) assemblies located in fractions 4 to 6 were specifi-
cally sensitive to our agents D36,8–10 and D3D3. Therefore, these species were further characterized in 
detail. According to the calibration of the density gradient with a set of globular proteins with known 
s-values, the Aβ (1–42) assemblies in fractions 4 to 6 had s-values of about 7 S (Supplementary Figure 1a). 
Atomic force microscopy (AFM) analysis of fraction 4 to 6 revealed assemblies in spherically shaped 
particles with heights of 4.7 nm and diameters corrected for the tip dimensions of 8.7 nm (Fig. 3a and 
Supplementary Figure 2). Modelled as oblate spheroids with an axial ratio of ~2, these Aβ (1–42) oli-
gomers have a molecular weight of about 104 kDa, which corresponds to about 23 monomeric units. 
This value is in good accordance with the estimated s-value of 7 S. Circular dichroism (CD) measure-
ments of the oligomers revealed a spectrum with β -sheet characteristics (Fig.  3b). However, since the 
Aβ (1–42) particles were negative for Thioflavin T (ThT) fluorescence staining (Supplementary Figure 3), 
we conclude that the secondary structure of the oligomers differs from regular amyloid cross-β fibrils, 
which typically exhibit strong ThT fluorescence. The DGC derived Aβ (1–42) oligomers exhibited high 
cytotoxicity to differentiated human SH-SY5Y neuroblastoma cells11–13 (Fig. 3c), thus meeting a further 
criterion of toxic Aβ (1–42) oligomers involved in AD pathogenesis.
Aβ oligomer elimination by D3 and D3D3. Here, we demonstrate the power of the Aβ -QIAD assay 
by quantitatively comparing the outcome of the assay for two therapeutically interesting agents. The first 
agent is a mirror image phage display8,14 selected D-enantiomeric peptide, termed “D3”, which inhibits 
the formation of regular Aβ (1–42) fibrils, removes Aβ (1–42) oligomers and reduces Aβ (1–42) cytotoxic-
ity in vitro. In vivo, D3 binds to amyloid plaques10, is able to reduce plaque load, decrease inflammation 
and enhance cognition in a transgenic AD mouse model even after oral application6,9. The second agent 
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Figure 1. Scheme of the QIAD assay consisting of the following steps i) preparation of Aβ (1–42) 
assemblies containing the target aggregate species by Aβ (1–42) pre-incubation; ii) incubation with and 
without the agent of interest; iii) separation of Aβ (1–42) assemblies by density gradient centrifugation and 
subsequent fractionation; iv) determination of the total Aβ (1–42) amount in each fraction by integrating 
the Aβ (1–42) absorption signal during RP-HPLC analysis and the concluding visualisation of the Aβ (1–42) 
oligomer removal. The drawing of the magnifying glass was drawn by O. Brener
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Figure 2. Quantification of Aβ(1–42) in different assembly states by QIAD. (a) RP-HPLC chromatograms 
of 1.8 ng of either freshly resolved or incubated (2.5, 19 and 60 h) Aβ (1–42) were mixed with 40% iodixanol 
to simulate the properties of the density gradient fractions and analysed by RP-HPLC. Iodixanol elutes 
clearly separated from Aβ (1–42) (retention time 2-5 min), enabling UV spectroscopic analysis of Aβ (1–42) 
concentrations. Chromatograms of all Aβ (1–42) samples regardless of their degree of aggregation reveal the 
same retention times and peak areas. (b) Chromatograms for each fraction obtained from density gradient 
centrifugation (DGC) are presented with a constant offset for clarity. The peak at 2 to 4 min corresponds to 
the density gradient material iodixanol, whereas the peak at 12.5 min corresponds to Aβ (1-42). (c) Bar chart 
showing the Aβ (1–42) distribution after DGC of pre-incubated Aβ (1–42). Aβ (1–42) concentrations in each 
fraction were determined by integration of the Aβ (1–42) absorption in the RP-HPLC chromatograms shown 
in (b). Aβ (1-42) oligomers of interest (dashed box) are located in fractions 4 to 6.
www.nature.com/scientificreports/
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Figure 3. Characterization of Aβ oligomers. (a) AFM of Aβ (1–42) oligomers from pooled fractions 5 and 
6. Scale bar 200 nm. (b) Far-UV CD spectroscopy of Aβ (1–42) oligomers from pooled fractions 5 and 6 
indicating a pre-dominantly β -sheet secondary structure. (c) Toxicity of Aβ (1–42) oligomers from pooled 
fractions 5 and 6 tested by MTT cell viability. RA/BDNF differentiated SH-SY5Y cells were treated with 
Aβ (1–42) oligomers (dark grey) at monomer concentrations of 4, 2 and 0.8 μ M with corresponding buffer 
dilution controls containing 16, 8 and 3.2% iodixanol (light grey), or with ultrasonicated Aβ (1–42) fibrils 
(black) at a monomer concentration of 4 μ M and the corresponding buffer without iodixanol (white) as 
control. All given Aβ (1–42) assembly concentrations relate to Aβ (1–42) monomers.
www.nature.com/scientificreports/
6Scientific RepoRts | 5:13222 | DOi: 10.1038/srep13222
is a head-to-tail tandem version of D3, termed “D3D3”, that is expected to have enhanced efficacy due to 
increased avidity. As shown in Fig. 4a, both agents yielded significant reduction of Aβ (1–42) oligomers in 
DGC fractions 4 to 6 in comparison to agent-free controls. D3 (32 μ g/ml, 20 μ M) and D3D3 (32 μ g/ml, 
10 μ M) reduced Aβ (1–42) oligomers by 50% and 96%, respectively. The oligomer elimination efficiency 
is defined as the percentage of reduction of Aβ (1–42) contents in fractions 4 to 6 in presence of agent 
as compared to absence of agent. D3D3 proved to be significantly more efficient than D3 (Fig. 4a and 
Supplementary Figure 4). Notably, monomeric Aβ (1–42) located in DGC fractions 1 and 2 were negligi-
bly affected by D3 and D3D3. The net reduction of Aβ (1–42) oligomers by D3 and D3D3 was balanced 
by an increase of high-molecular weight aggregates located in DGC fractions 9 to 12 or in fractions 12 to 
15, respectively (Fig. 4a and Supplementary Figure 4). Increase of Aβ (1–42) content in DGC fractions 9 
to 12 or in fractions 12 to 15 does not mean that formation of pre-fibrils or fibrils is induced by D3 and 
D3D3. The Aβ (1–42) species in fractions 9 to 15 have completely different morphologies depending on 
presence or absence of D3 or D3D3. Thus, D3 and D3D3 are active in vivo and obviously both have the 
same mechanism of action, which is elimination of Aβ (1–42) oligomers of the same size as shown in vitro 
in the QIAD assay, with D3D3 being more efficient than D3, and with D3D3 yielding larger co-aggregates 
than D3. D3-Aβ -co-aggregates were shown previously to be non-toxic, non-amyloidogenic, amorphous 
and ThT negative6.
Correlation of the in vitro and in vivo results. To verify the hypothesis that increased efficiency 
in Aβ oligomer elimination of an agent correlates with in vivo potency of the agent, therapeutic effects 
of D3 and D3D3 were investigated in the transgenic mouse model TBA2.1, which is expressing human 
N-terminally truncated and pyroglutamated Aβ 15. Thus, the analysis of protein levels in brains of TBA2.1 
mice showed substantial amounts of both Aβ and pE3–Aβ 15. Three groups of TBA2.1 mice were treated 
either with phosphate buffered saline, D3 or D3D3 (5.1 ± 0.1 mg per kg body weight per day, i.p., for 4 
weeks using minipumps). Their phenotypes before and after the treatment were assessed using SHIRPA 
tests16. Importantly, D3D3-treated mice did not show significant worsening of their phenotypes in the 
SHIRPA test, whereas the phenotypes of D3-treated mice and saline-treated mice worsened significantly, 
during the four weeks duration of the experiment (Fig.  4b). Thus, D3D3 was more efficient than D3, 
exactly as predicted from the Aβ -QIAD assay results of both compounds. Despite this nice correlation, 
the observed in vivo effects of D3 and D3D3 treatment are not necessarily exclusively due to the Aβ 
oligomer elimination activity of both compounds. One may well think of other potential activities, e.g. 
interference with described Aβ oligomer receptors like cellular prion protein17–19, N-methyl-D-aspartate 
receptor or paired immunoglobulin-like receptor B20, overall inflammation reduction9, or interference 
with the postulated Aβ oligomer induced cell membrane permeation1,21,22.
After having compared efficacies of D3 and D3D3 in the TBA2.1 model, we wanted to further verify 
the in vivo efficacy of D3D3, and thus, treated the transgenic AD mouse model Tg-SwDI23 with this pep-
tide. Intraperitoneal application of D3D3 (1.4 ± 0.15 mg per kg body weight per day for 4 weeks, using 
implanted minipumps) led to significant reduction of plaque load in comparison to the saline treated 
control group (Fig. 4c and Supplementary Figure 5). Cognitive deficits of Tg-SwDI mice, as measured in 
the object recognition test (Supplementary Figure 6), were significantly improved upon D3D3 treatment 
(Fig. 4d). Behavioural side effects caused by D3D3 treatment as measured by open field and zero maze 
tests were not detected.
Further compounds tested by QIAD. To demonstrate the usefulness of the QIAD assay, we applied 
it to a number of agents, which were previously reported to influence Aβ (1–42) assembly distribution and/
or did show efficacy in cognition improvement of transgenic AD animals, like homotaurine (Alzhemed), 
scyllo-inositol, and epigallocatechin gallate (EGCG). EGCG clearly converted Aβ (1–42) monomers into 
larger particles (Fig. 5a and Supplementary Figure 7), exactly as had been reported24. Homotaurine and 
scyllo-inositol did not have any significant effect on the Aβ (1–42) aggregate size distribution even at 
2 mM concentrations (Fig. 5a). This is in agreement with recent work reporting that scyllo-inositol does 
not have any effect on Aβ toxicity and Aβ oligomer formation25. Also, for homotaurine negative results 
on Aβ aggregation were reported and discussed in relation to failed clinical trials26.
Recently, 6-methoxy-2-(4-dimethylaminostyryl) benzofuran (KMS88009) (Supplementary Figure 8) 
was reported to reduce oligomeric Aβ species and to reverse cognitive deficits in AD transgenic mice27,28. 
Because KMS88009 was not water soluble, but needed DMSO and Tween20 for solvation, it was neces-
sary to adapt the QIAD assay conditions to contain 1.6% DMSO and 0.2% Tween20 in the solvent (final 
concentrations). Figure 5b shows the Aβ (1–42) aggregate size distributions with and without KMS88009. 
This clearly shows that QIAD assay conditions can be adapted to experimental needs, easily. Similar to 
EGCG, KMS88009 reduces the amount of Aβ (1–42) monomers in DGC fractions 1 and 2 in favour of 
oligomer sized particles in fractions 5 and 6 (Fig.  5b). This, however, does not necessarily mean that 
KMS88009 generates toxic Aβ (1–42) oligomers. The increase of Aβ amounts in fractions 4 to 6 is not 
the opposite of the reduction of Aβ amounts in fraction 4 to 6, because the newly generated particles are 
most likely not consisting of pure Aβ (1–42), but rather are co-assemblies of Aβ (1–42) and KMS88009.
Another example compound, ZAβ 3W, which is an Affibody protein that prevents Aβ toxicity by 
sequestration of monomeric Aβ 29,30, induced reduction of Aβ (1–42) content in fraction 1 and an increase 
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Figure 4. Effects of D3 and D3D3 in vitro and in vivo. (a) QIAD assay. After pre-incubation of 80 μ M 
Aβ (1–42) for 4.5 h at RT and further incubation for 40 min at RT with or without agent, Aβ (1–42) size 
distributions in the absence (black) or presence of either D3 (light gray, 32 μ g/ml, 20 μ M) or D3D3 (dark 
gray, 32 μ g/ml, 10 μ M) were analyzed by DGC. Aβ (1–42) concentrations as determined by UV absorption 
during RP-HPLC are shown with standard deviations. Aβ (1–42) oligomers of interest (dashed box) are 
located in fractions 4 to 6. (Inset) Magnification of boxed area displaying significant differences of Aβ (1–42) 
oligomer contents between untreated (black), D3 treated (light grey) and D3D3 treated Aβ (1–42) (dark 
grey). Paired U-test; *p ≤ 0.05, **p ≤ 0.01 (b) Assessment of TBA 2.1 phenotype using part of the SHIRPA 
test battery before (black) and after i.p. treatment (white) for 4 weeks with phosphate buffered saline (n = 7), 
or D3 (n = 8) or D3D3 (n = 8) (5.1 ± 0.1 mg per kg body weight per day). Repeated measures ANOVA 
before vs. after p = 0.0027, paired t-test (hypothesized difference ≥ 0) before vs. after, *p = 0.035, **p = 0.010. 
(c) Plaque load reduction of D3D3 treated Tg-SwDI mice (n = 10) (white) as compared to saline-treated 
controls (n = 9) (black) in hippocampus and cortex. Unpaired t-test (hypothesized difference ≥ 0) D3D3 
vs. saline, *p = 0.020, **p < 0.0001. (d) Object recognition test of Tg-SwDI mice treated either with D3D3 
or saline (control). Preference for the new object (black) is expressed as exploration time in comparison 
with exploration of a familiar object (white); Paired t-test (hypothesized difference ≥ 0) before vs. after, 
**p = 0.016. n.s.: not significant (p > 0.05).
www.nature.com/scientificreports/
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in Aβ (1–42) content in fraction 2, exactly as expected for the formation of a 1:1 ZAβ 3W-Aβ complex 
with an s-value of 2.4 S (Fig. 5c).
Predictive power of the QIAD assay. The hereby described Aβ -QIAD assay for analysis of 
agent-induced Aβ oligomer elimination allows comprehensive and reliable in vitro screening of drug 
candidates for maximum efficacy in the elimination of cytotoxic Aβ oligomers. Analysis of Aβ (1–42) 
Figure 5. QIAD assay results of agents that were previously reported to influence Aβ(1–42) assembly 
distribution and/or did show efficacy in cognition improvement of transgenic AD animals. Shown are 
Aβ (1-42) particle size distributions after pre-incubation of 80 μ M Aβ (1-42) for 4.5 h at RT and further 
incubation for 40 min without (black bars) or with agent. Agents were (a) 2 mM homotaurine (red), scyllo-
inositol (green) or epigallocatechin gallate (yellow), (b) 200 μ M 6-methoxy-2-(4-dimethylaminostyryl) 
benzofuran (KMS88009, green), and (c) 54 μ M ZAβ 3W (red). Note that the assay with KMS88009 contained 
1.6% DMSO and 0.2% Tween20 (final concentrations). Therefore, the control without agent was done in 
presence of 1.6% DMSO and 0.2% Tween20 (red bars in (b)).
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content in DGC fractions by RP-HPLC allows quantitative comparison between various drug candi-
dates. Although Aβ oligomer elimination is not necessarily the only mechanism of compounds that show 
in vivo efficacy in AD animal models, Aβ oligomer elimination is — from the current point of view — the 
most promising option for causative AD treatment and therapy. The observed relation between Aβ oli-
gomer elimination of D3 and D3D3 and their in vivo results strengthens the role of Aβ oligomers in AD 
pathology and the role of D3 and D3D3 as potential causative agents for AD treatment. Furthermore, 
the assay will help to avoid testing of ineffective compounds in animals and time consuming in vivo 
assays or even clinical trials. The QIAD assay is adjustable for any aggregation-prone peptide or protein.
Methods
Ethics statement. All experiments were carried out in compliance with the USPHS Guide for Care 
and Use of Laboratory Animals and approved by the Institutional Animal Care and Use Committee 
(IACUC) as well as in conformance with the German Protection of Animals Act (TierSchG §§ 7–9) 
and with permit of an Animal Protection Committee at the local agency (Landesamt für Natur und 
Verbraucherschutz (LANUV), Northrhine-Westphalia, Germany, permit ID: AZ84-02.04.2011.A359)
QIAD assay. The QIAD assay involves four steps: (i) pre-incubation of Aβ (1–42); (ii) addition of the 
agent to oligomer-enriched Aβ (1–42) samples; (iii) the density gradient centrifugation step; and (iv) the 
quantification of Aβ (1–42) assemblies by RP-HPLC (Fig. 1).
1. Pre-incubation of Aβ. Pre-incubation of the Aβ (1–42) solution leads to an increase of the amount 
of material with higher s-values, penetrating deeper into the gradient during centrifugation (details 
regarding the gradient are given below). A pre-incubation of 80 μ M Aβ (1–42) between 4.5 h and 6 h 
in 10 mM sodium phosphate buffer pH 7.4 at RT and shaking (600 rpm) was found to be the best 
condition at which the amount of oligomers residing in the middle of the gradient was maximized 
without the appearance of signals in bottom fractions, indicating the absence of large or fibrillar 
aggregates in the sample at the investigated time point. The generated oligomeric species were located 
in fractions 4 to 6. In this area of the gradient, proteins with s-values of about 7 S and molecular 
weights in the range of 66 to 150 kDa were expected following the centrifugation step. This expecta-
tion is based on the analysis of the distribution of standard proteins used for the calibration of the 
gradient (Supplementary Figure 1). The concentration of iodixanol (OptiPrep, AXIS-SHIELD, Oslo, 
Norway) was about 20% (w/v), giving a density of 1.112 g/cm3. Based on the proteins used for the 
calibration of the gradient, the size of oligomers in these fractions was in the range of 50 to 150 kDa.
2. Our previously described mirror image phage display selected d-peptide D3 and a derivative thereof 
were applied as drug candidates. Compounds were added to the pre-incubated Aβ (1–42) solution 
40 min before loading the sample onto the gradient.
3. Density gradient centrifugation4,5,31 offers an approach to fractionate aggregates formed by Aβ (1–42) 
by their size and shape for further characterization. Analysis of solutions of synthetic Aβ (1–42) by 
iodixanol density gradient centrifugation revealed the s-value distribution of monomers and assem-
blies at the time point of analysis. A discontinuous gradient of iodixanol was pre-formed by layering 
260 μ l of 50% (w/v) iodixanol at the bottom of an 11 × 34 mm polyallomer centrifuge tube, over-
laid by 260 μ l of 40% (w/v), 260 μ l of 30% (w/v), 780 μ l of 20% (w/v), 260 μ l of 10% w/v), and 100 μ l 
of 5% (w/v) iodixanol. The total volume of the with 10 mM sodium phosphate (pH 7.4) buffered 
non-linear gradient was 1920 μ l. The top of the gradient was overlaid by a 100 μ l aliquot of incubated 
Aβ (1–42) in 10 mM sodium phosphate buffer pH 7.4. The samples were spun at 259,000 × g for 3 h at 
4 °C in a TL 100 ultracentrifuge with a TLS-55 rotor (both Beckman Instruments, Brea, USA). After 
the centrifugation, 14 fractions of 140 μ l were harvested with a pipette by upward displacement. The 
pellet of each tube (ca. 60 μ l remaining volume) was mixed with 60 μ l 6 M guanidinium hydrochlo-
ride and boiled for 10 min. The resulting solution represents fraction 15. Fraction 1 from the top of 
the gradient was the least dense, and fraction 15 from the bottom was the densest fraction.
4. All the fractions were analyzed with respect to their Aβ (1–42) content by RP-HPLC (see below for a 
detailed description).
As a control for each density centrifugation run, a sample without the added agent was used. Statistical 
evaluation of experimental results from eleven independent control density gradient centrifugation anal-
yses demonstrated the good reproducibility of the procedure (Fig. 4a, black bars).
Please note: All ligands (inhibitors), but ZAβ 3W, used in this work are small molecules when com-
pared with Aβ (1–42). Therefore, even 1:1 stochiometric complexes will not increase the molecular 
weight of Aβ (1–42) oligomers enough to be detected as significant difference in the density gradient 
centrifugation.
Analytical RP-HPLC. Quantifications of Aβ (1–42) present in DGC fractions were performed 
by RP-HPLC on a Zorbax SB-300 C8 column (5 μ m, 4.8 × 250 mm, Agilent, Waldbronn, Germany) 
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connected to an Agilent 1260 Infinity system. Denaturation of Aβ (1–42) assemblies and separation of 
Aβ (1–42) from other compounds, especially from the density gradient forming iodixanol, was achieved 
using 30% (v/v) acetonitrile, 0.1% (v/v) trifluoroacetic acid in H2O as the mobile phase, an elevated 
column temperature of 80 °C and a flow rate of 1 ml/min. Applied sample volumes were 20 μ l. Eluting 
substances were detected by their UV absorbance at 215 nm. Data recording and peak area integration 
was achieved by the program package ChemStation (Agilent, Waldbronn, Germany). Calibration of the 
column was achieved with Aβ (1–42) solutions of known concentrations (0 to 25 μ M Aβ (1–42)) and the 
resulting linear equation from a plot of peak area vs. Aβ (1–42) concentration allowed the calculation of 
molar Aβ (1–42) concentrations (from corresponding peak areas) (Supplementary Figure 9).
The quantitative analysis of Aβ (1–42) amounts in every fraction allows us to determine the recovery 
rate R:
=
+ ∑
( )
= ·
·
R
c V c V
c V 1
P P n n F1
14
0 0
with cP the Aβ (1–42) concentration in the pellet (15th fraction), cn the Aβ (1–42) concentrations in frac-
tions 1 to 14, c0 the Aβ (1–42) concentration in the initial sample, Vf the volume of the fractions 1 to 14 
(140 μ l), VP the volume of the pellet (15th fraction), and V0 the volume of the initial sample. In the case 
the calculated recovery rates were higher than 100%, the Aβ (1–42) contents of all fractions were divided 
by the effective recovery rate.
Limiting for detection of Aβ (1–42) was the sensitivity of the UV detector connected to the HPLC. 
In our case the sensitivity limit was 20 nM Aβ (1–42). In principle, the sensitivity can easily be increased 
for example by coupling of RP-HPLC with mass spectrometry, but there was no need to do that for the 
experiments described in the manuscript. Thus, the QIAD could be easily performed with nano- or even 
picomolar Aβ concentrations.
Animals. For study #1 23 four months old female tg/tg TBA2.1 (insertion of precursor of N-terminally 
modified pyroglutamate-Aβ in C57BL/6 x DBA1 background) and for study #2 19 four months old 
female Tg-SwDI mice (human APP with Swedish K670N/M671L, Dutch E693Q and Iowa D694N muta-
tions on a C57BL/6 background) were used. Group sizes were decided on the basis of data from previous 
studies6. Inclusion and exclusion criteria were determined in advance. Because of the known heterogene-
ity of phenotypes between different sexes, only female mice with an age between 3, 5 and 4 months were 
included in the study. Exclusion criteria were defined as weight loss of ≥ 15%, surgical site infection and 
very serious general conditions in addition to the normal phenotype of Tg-SwDI or TBA2.1 mice. All 
animals fulfilled the inclusion criteria and no animal was excluded after enrolment in the study.
The animals were housed 4/cage in a controlled environment (temperature 22 °C, humidity 50–60%, 
light from 07:00 to 19:00), food and water were available ad libitum. The implantation of the Alzet min-
ipumps was performed intraperitoneal (for study #1, model #1004; delivery rate: 0.11 μ l/h duration: 4 
weeks; for study #2 model #2004; delivery rate: 0.25 μ l/h, duration: 4 weeks). During the treatment the 
animals were housed individually.
In study #1, the D3D3 peptide (n = 8) was compared with the D3 peptide (n = 8) and the control 
(n = 7, phosphate buffered saline). The applied peptide amount was 2.8 mg/pump.
In study #2, treatment took place with the D3D3 peptide (n = 10) and control group (n = 9, saline). 
Animals were divided into two groups based on similar average body weight. The applied peptide amount 
was 1 mg/pump, 0.9 mg of unconjugated peptide and 0.1 mg peptide conjugated with fluorescein.
The Alzet minipumps were filled with the appropriate solutions and implanted into the peritoneal 
cavity.
Behavior and functional assessment. In study #1, selected tests from the primary screening of the 
SHIRPA test battery16 were used to assess levels of spinocerebellar function, muscle and lower motor neu-
ron functions, sensory function, neuropsychiatric function and autonomic function of the TBA2.1 mice. 
The following tests were used: abnormal body carriage, alertness, abnormal gait, startle response, loss of 
righting reflex, touch response, pinna reflex, cornea reflex, forelimb placing reflex, hanging behavior and 
pain response. An arena of 55 cm × 19.5 cm × 33 cm (L × H × W) was used for individual observation 
and analysis. The scoring values were from 0 (similar to wild type) to 3 (extremely changed compared 
to wild type). Before starting the treatment, mice were stratified into treatment groups using the afore-
mentioned tests and two days before the end of the treatment they were tested again. Experimenters were 
blind to group allocation. Additionally, the motor balance and motor coordination of TBA2.1 mice were 
determined on the rotarod for 2 days before start and end of treatment using a published protocol15. In 
the morning of the first day mice were trained to stay on the rod for at least 60 s at 10 rpm. The three 
following test sessions, one in the afternoon and two at the second day, started with habituation for 
30 min before the mice ran three times on the rotarod with an accelerated beam from 4 till 40 rpm in 
5 min. After mice falling off the rod latency time was recorded.
During the last week of treatment in study #2, animals were tested in four different behavioral tests 
to assess cognition and to monitor side effects. Experimenters were not informed about group allocation. 
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First the open field test was conducted. The maze consisted of an arena of 42 cm × 42 cm with clear 
Plexiglas sides (20 cm high). The animal was put into the arena and observed for 4 min, with a camera 
driven tracker system, Ethovision 8.5 (Noldus, Wageningen, The Netherlands). The arena was subdivided 
into two areas, the “open” center and the area by the wall. The system recorded the position of the animal 
in the arena at 5 frames/second and the data were analyzed regarding time spent in each area (center vs. 
wall), similarly speed and distance were recorded. For disinfection the apparatus was wiped down with 
chlorhexidine and 70% ethanol and allowed to airdry.
Next, the zero maze test was conducted. The maze consisted of a circular arena with a diameter of 
65 cm and four areas of equal size, two without walls, and two with walls of nontransparent material. The 
animal was put in the arena, and observed for 4 min, with a camera driven tracking system, Ethovision 
8.5. The time spent in each area (open vs. closed) was recorded, similarly speed and distance were also 
recorded.
Subsequently the object recognition test (ORT) was carried out in a maze consisting of a rectangular 
polycarbonate box, with partitions separating the box into three chambers. The partitions had openings 
that allowed the animal to move freely from one chamber to another. The animal was monitored by the 
Ethovision 8.5 tracking system 8.5. On day one two objects were placed on each side of the box. The 
mouse was placed in the box and allowed to move freely throughout the apparatus for a 10-minute test 
session. After 24 h, a new object replaced one of the “old” objects and the mouse was put in the box and 
allowed to move freely throughout the box over a 4-minute test session. The time spent with each object 
and the transitions between the objects were recorded. The apparatus was wiped down with chlorhex-
idine followed by ethanol and water and dried with paper towels for each mouse tested.
Finally, the mice were tested for 5 days in a Morris water maze (MWM). The maze consisted of a 
blue circular tank of clear water (23 ± 1 °C). The mice were placed in the water at the edge of the pool 
and allowed to swim in order to locate a hidden, but fixed escape platform, using extra maze cues. On 
day 1, the mice were placed in the pool and allowed to swim freely for 60 s or until the hidden platform 
was found; each animal was tested for four trials per day. A maximum swim time per trial of 60 s was 
allowed; if the animal did not locate the platform in that time, it was placed upon it by the experimenter 
and left there for 10 s. The intertrial interval was 120 s. Each start position (east, north, south and west) 
was used equally in a pseudo random order and the animals were always placed in the water facing the 
wall. The platform was placed in the middle of one of the quadrants of the pool (approximately 30 cm 
from the side of the pool). The mouse’s task throughout the experiment was to find the platform. The 
animal was monitored by Ethovision 7.1.
Statistics. Data were averaged and represented as mean ± standard error of mean (SEM). Statview, 
Version 5.0.1 served for all calculations, p > 0.05 was considered not significant (“n.s.”).
SHIRPA. Repeated measures ANOVA before v/s after p = 0.0027, Paired t-test (hypothesized difference 
≥ 0) before v/s after, **p = 0.010, *p = 0.035.
Object Recognition Test. Paired t-test (hypothesized difference ≥ 0) before v/s after, *p = 0.016.
Plaque Load. Unpaired t-test (hypothesized difference ≥ 0) D3D3 v/s saline, *p = 0.020, **p < 0.0001.
QIAD Assay. SigmaPlot, Version 11.0 served for statistical calculations.
Paired Mann-Whitney U-test. Aβ without ligand n = 11, Aβ with D3, D3D3, EGCG, homotaurine, 
scyllo-inositol, KMS88009 and ZAβ 3W n = 4.
*P ≤ 0.05, **P ≤ 0.01 (fraction 4: Aβ vs Aβ + D3, p = 0.005; Aβ + D3 vs Aβ + D3D3, p = 0.029;
fraction 5: Aβ vs Aβ + D3, p = 0.005; Aβ + D3 vs Aβ + D3D3, p = 0.029;
fraction 6: Aβ vs Aβ + D3, p = 0.007; Aβ + D3 vs Aβ + D3D3, p = 0.029).
The detailed descriptions of further methods like atomic force microscopy, cell culture and differenti-
ation, cell viability assay, ThT fibril formation assay, circular dichroism spectroscopy, histopathology, syn-
thesis of (E)-4-(2-(6-methoxybenzofuran-2-yl)vinyl)-N,N-dimethylaniline are given in the Supporting 
Information.
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